PROCEPT BioRobotics Corporation (PRCT) Stock Analysis & Investment Frameworks
PROCEPT BioRobotics Corporation (PRCT) stock analysis on Invetso. Review PROCEPT BioRobotics Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
PROCEPT BioRobotics Corporation Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
PROCEPT BioRobotics Corporation Key Financial Metrics
- Market Cap: $1.18B
- Revenue: $308.05M
- ROE: -33.23%
- ROIC: -29.16%
- Dividend Yield: N/A
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.